Literature DB >> 19428891

SopB of Salmonella enterica serovar Typhimurium is a potential DNA vaccine candidate in conjugation with live attenuated bacteria.

Arvindhan G Nagarajan1, Sudhagar V Balasundaram, Jessin Janice, Guruswamy Karnam, Sandeepa M Eswarappa, Dipshikha Chakravortty.   

Abstract

The immune response against Salmonella is multi-faceted involving both the innate and the adaptive immune system. The characterization of specific Salmonella antigens inducing immune response could critically contribute to the development of epitope based vaccines for Salmonella. We have tried to identify a protective T cell epitope(s) of Salmonella, as cell mediated immunity conferred by CD8+ T cells is the most crucial subset conferring protective immunity against Salmonella. It being a proven fact that secreted proteins are better in inducing cell mediated immunity than cell surface and cytosolic antigens, we have analyzed all the genbank annotated Salmonella pathogenicity island 1 and 2 secreted proteins of Salmonella enterica serovar Typhimurium (S. typhimurium) and S. enterica serovar Typhi (S. typhi). They were subjected to BIMAS and SYFPEITHI analysis to map MHC-I and MHC-II binding epitopes. The huge profile of possible T cell epitopes obtained from the two classes of secreted proteins were tabulated and using a scoring system that considers the binding affinity and promiscuity of binding to more than one allele, SopB and SifB were chosen for experimental confirmation in murine immunization model. The entire SopB and SifB genes were cloned into DNA vaccine vectors and were administered along with live attenuated Salmonella and it was found that SopB vaccination reduced the bacterial burden of organs by about 5-fold on day 4 and day 8 after challenge with virulent Salmonella and proved to be a more efficient vaccination strategy than live attenuated bacteria alone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19428891     DOI: 10.1016/j.vaccine.2009.02.092

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Haloarchaeal gas vesicle nanoparticles displaying Salmonella antigens as a novel approach to vaccine development.

Authors:  P DasSarma; V D Negi; A Balakrishnan; J-M Kim; R Karan; D Chakravortty; S DasSarma
Journal:  Procedia Vaccinol       Date:  2015

2.  Enhancement of immune responses by an attenuated Salmonella enterica serovar Typhimurium strain secreting an Escherichia coli heat-labile enterotoxin B subunit protein as an adjuvant for a live Salmonella vaccine candidate.

Authors:  Jin Hur; John Hwa Lee
Journal:  Clin Vaccine Immunol       Date:  2010-12-15

3.  Antigen-encapsulating host extracellular vesicles derived from Salmonella-infected cells stimulate pathogen-specific Th1-type responses in vivo.

Authors:  Winnie W Hui; Lisa E Emerson; Beata Clapp; Austin E Sheppe; Jatin Sharma; Johanna Del Castillo; Mark Ou; Gustavo H B Maegawa; Carol Hoffman; Joseph Larkin Iii; David W Pascual; Mariola J Edelmann
Journal:  PLoS Pathog       Date:  2021-05-06       Impact factor: 6.823

4.  Salmonella enterica serovar Typhimurium lacking hfq gene confers protective immunity against murine typhoid.

Authors:  Uday Shankar Allam; M Gopala Krishna; Amit Lahiri; Omana Joy; Dipshikha Chakravortty
Journal:  PLoS One       Date:  2011-02-09       Impact factor: 3.240

Review 5.  Gas Vesicle Nanoparticles for Antigen Display.

Authors:  Shiladitya DasSarma; Priya DasSarma
Journal:  Vaccines (Basel)       Date:  2015-09-07

6.  Evaluation of Salmonella enterica serovar Typhimurium TTSS-2 deficient fur mutant as safe live-attenuated vaccine candidate for immunocompromised mice.

Authors:  Vikalp Vishwakarma; Niladri Bhusan Pati; Himanshu Singh Chandel; Sushree Sangeeta Sahoo; Bhaskar Saha; Mrutyunjay Suar
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

7.  Oral Deliverable Mucoadhesive Chitosan-Salmonella Subunit Nanovaccine for Layer Chickens.

Authors:  Sankar Renu; Ashley D Markazi; Santosh Dhakal; Yashavanth S Lakshmanappa; Revathi Shanmugasundaram; Ramesh K Selvaraj; Gourapura J Renukaradhya
Journal:  Int J Nanomedicine       Date:  2020-02-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.